Belvedere Trading’s Gilead Sciences GILD Stock Holding History

Belvedere Trading’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,800	Closed	-$1.1M	–	1159
2022 Q3	$1.1M	Buy	+15,800	New	+$996K	0.04%	39

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Belvedere Trading's GILD Position: Q1 2023 in Review

Belvedere Trading sold out of Gilead Sciences (GILD) in Q1 2023, closing a stake of 443 shares — an estimated $38K sold.

Belvedere Trading first reported a position in GILD in Q4 2014 and held it in 2 quarters. The position peaked at $3.21M in Q4 2014. 1,735 funds tracked by Wall St. Rank hold GILD as of Q1 2023.

Belvedere Trading reported no remaining Gilead Sciences position as of Q1 2023 after selling out during the quarter.
Belvedere Trading sold 443 Gilead Sciences shares in Q1 2023, an estimated $38K.
Belvedere Trading first reported a position in Gilead Sciences in Q4 2014 and held it in 2 quarters.
Belvedere Trading's Gilead Sciences position peaked at $3.21M in Q4 2014.
1,735 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.